Tradestie Institutional Equity Comparison Engine

CRMD vs OGEN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CRMD Overall Edge

CRMD Captures Institutional Edge (3โ€“1 Pillars ยท 10โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CorMedix Inc. (CRMD) driven by superior Valuation, Growth & Margin, Momentum & Technical while OGEN counters with relative strength in Options & Structure. Fundamentally, CRMD trades at 49.0x Forward P/E with 41.0% operating margin (-47.7% YoY revenue) versus OGEN at N/M Forward P/E and 0.0% operating margin (-91.3% YoY). In options structure, CRMD sits in BREAKDOWN (25th %ile IV; Dealer Gamma Walls on Pro) against OGEN sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner CRMD
CRMD 49.0x vs OGEN N/M Fwd P/E
Growth & Margin Winner CRMD
Op Margin 41.0% vs 0.0% ยท YoY -47.7% vs -91.3%
Momentum & Technical Winner CRMD
1Y -56.2% vs -83.7% ยท 52W Pos 3% vs 2%
Options & Structure Winner OGEN
BREAKDOWN (25th %ile IV) vs UNCLASSIFIED (N/A IV)
CRMD NASDAQ
CorMedix Inc.
Pharmaceutical Preparations
$4.92
+5.47% 1D
Market Cap $384.7M
1M Return -32.3%
1Y Return -56.16%
Forward P/E 49.0x
Unified AI Score
53.2 / 100 HOLD
Tech 60.0 Fund 60.0 Flow 69.0 Mom 55.0
OGEN NYSE American
Oragenics Inc.
Pharmaceutical Preparations
$0.19
-7.36% 1D
Market Cap $1.6M
1M Return -57.19%
1Y Return -83.67%
Forward P/E N/M
Unified AI Score
41.7 / 100 SELL
Tech 25.0 Fund 46.0 Flow 50.0 Mom 55.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CRMD -56.16% OGEN -83.67% Spread: +27.51 pp (CRMD Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period CRMD Revenue OGEN Revenue CRMD Op. Margin OGEN Op. Margin Margin Edge
FY2018 $0M N/A -6250.4% N/A CRMD
FY2019 $0M N/A -7416.3% N/A CRMD
FY2020 $0M N/A -11378.4% N/A CRMD
FY2021 $0M $0M -15417.5% -18130.3% CRMD
FY2022 $0M $0M -46819.9% -10964.6% OGEN
FY2023 N/A $0M N/A -55519.9% OGEN
FY2024 $40M N/A -51.4% N/A CRMD
FY2025 $310M N/A 48.2% N/A CRMD

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CRMD (10) vs OGEN (0)
Institutional Metric CRMD OGEN Criterion Row Winner
Market Capitalization Scale $384.7M $1.6M Larger Scale CRMD
Trailing P/E Ratio Valuation 2.4x N/M Lower Multiple CRMD
Forward P/E Ratio Valuation 49.0x N/M Lower Multiple CRMD
Revenue Growth (YoY) Growth -47.7% -91.3% Higher Growth CRMD
Operating Margin (TTM) Profitability 41.0% 0.0% Higher Margin CRMD
Net Profit Margin Profitability 15.5% 0.0% Higher Margin CRMD
Return on Equity (ROE) Capital Efficiency 15.3% -1307.1% Higher ROE CRMD
52-Week Range Position Momentum 3% ($5โ€“$13) 2% ($0โ€“$1) Stronger Trend CRMD
Beta / 30D Volatility Risk Regime 1.20ฮฒ ยท 107% Vol 1.18ฮฒ ยท 153% Vol Lower Realized Risk CRMD
Unified Institutional Score Composite Signal 53.2 / 100 (HOLD) 41.7 / 100 (SELL) Higher Composite CRMD

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CRMD vs OGEN Buy Guide
CRMD BREAKDOWN
109d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 25th %ile
IV Regime Compressed (<25th %ile)
Live CRMD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
OGEN UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live OGEN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CRMD nor OGEN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.